ArticleNature communications2020

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.

Daniel Baumann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.